• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Abbott Laboratories

    6/20/25 4:05:52 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    11-K 1 tm2518166d1_11k.htm FORM 11-K

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549

     

     

     

    FORM 11-K

     

    FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS
    AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    (Mark One)

     

    xANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the fiscal year ended December 31, 2024

     

    OR

     

    ¨TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from ____________________ to _____________________

     

    Commission File Number 1-2189

     

    A.Full title of the plan and the address of the plan, if different from that of the issuer named below:

     

    ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

     

    B.Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

     

    ABBOTT LABORATORIES 

    100 Abbott Park Road 

    Abbott Park, Illinois 60064-6049

      

     

     

     

     

    FINANCIAL STATEMENTS AND 

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

    ABBOTT LABORATORIES STOCK RETIREMENT PLAN 

    DECEMBER 31, 2024 AND 2023

      

     

     

    C O N T E N T S

         
       Page 
         
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM   3 
          
    FINANCIAL STATEMENTS     
          
    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS   5 
          
    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS   6 
          
    NOTES TO FINANCIAL STATEMENTS   7 
          
    SUPPLEMENTAL SCHEDULE     
          
    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)   19 

     

     

     

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

     

    Plan Administrator and Plan Participants 

    Abbott Laboratories Stock Retirement Plan

     

    Opinion on the financial statements

     

    We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (the “Plan”) as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America.

     

    Basis for opinion

     

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

     

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

     

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

     

    3

     

     

    Supplemental information

     

    The schedule of assets (held at end of year) as of December 31, 2024 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

     

    /s/ GRANT THORNTON LLP

     

    We have served as the Plan’s auditor since 2002. 

     

    Chicago, Illinois 

    June 20, 2025

     

    4

     

     

    Abbott Laboratories Stock Retirement Plan        
    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS    
    December 31, 2024 and 2023        
    (Dollars in thousands)        
             
             
       2024   2023 
    Assets          
    Cash  $1,011   $81 
    Investments, at fair value   15,576,603    14,271,803 
    Employer contributions receivable   43,461    5,524 
    Notes receivable from participants   100,167    94,074 
    Accrued interest and dividend income   4,000    2,994 
    Due from brokers   30,426    121,715 
               
    Total assets   15,755,668    14,496,191 
               
    Liabilities          
    Investments sold short, at fair value   19,750    116,452 
    Accrued investment expenses   208    301 
    Due to brokers   10,441    159 
               
    Total liabilities   30,399    116,912 
               
    NET ASSETS AVAILABLE FOR BENEFITS  $15,725,269   $14,379,279 

     

    The accompanying notes are an integral part of these statements.

     

    5

     

     

    Abbott Laboratories Stock Retirement Plan    
    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
    Year ended December 31, 2024    

    (Dollars in thousands)

     

        

     

    Additions     
    Contributions     
    Employer  $244,939 
    Participant   412,674 
    Rollovers   41,699 
          
    Total contributions   699,312 
          
    Investment income     
    Net appreciation in fair value of investments   1,800,685 
    Interest and dividends   138,037 
          
    Net investment income   1,938,722 
          
    Interest income on notes receivable from participants   6,018 
          
    Total additions   2,644,052 
          
    Deductions     
    Benefits paid to participants   1,297,841 
    Other expenses   221 
          
    Total deductions   1,298,062 
          
    NET INCREASE   1,345,990 
          
    Net assets available for benefits     
    Beginning of year   14,379,279 
          
    End of year  $15,725,269 

     

    The accompanying notes are an integral part of this statement.

     

    6

     

     

    Abbott Laboratories Stock Retirement Plan 

    NOTES TO FINANCIAL STATEMENTS

    December 31, 2024 and 2023

     

     

     

    NOTE A - DESCRIPTION OF THE PLAN

     

    The following description of the Abbott Laboratories Stock Retirement Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

     

    General

     

    The Plan is intended to constitute a profit-sharing plan under Section 401(a) of the Internal Revenue Code of 1986, as amended (the “IRC”), with a cash or deferred arrangement under IRC Section 401(k), and a portion of the Plan is intended to constitute an employee stock ownership plan that meets the applicable requirements of IRC Sections 409 and 4975(e)(7). The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

     

    In general, United States employees of Abbott Laboratories (“Abbott”) and selected participating subsidiaries and affiliates may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

     

    Alight Solutions serves as the recordkeeper of the Plan. The Northern Trust Company (“Custodian” or “Trustee”) serves as the Plan’s custodian and trustee.

     

    Contributions and Vesting

     

    Contributions to the Plan are paid to the Abbott Laboratories Stock Retirement Trust (“Trust”). The Trust is administered by the Trustee and an investment committee (the “Committee”).

     

    Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate contribute from 2% and effective January 1, 2024 up to 50% (previously capped at 25%) of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from pretax earnings, after-tax earnings, or both. The Plan also permits Roth 401(k) contributions and has a Roth 401(k) conversion feature. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contributions are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options available under the Plan, except for investment options closed to new contributions.

     

    Employer matching contributions to the Plan are made each payroll period based on the participating employee’s eligible earnings, unless the employee has elected to participate as a Freedom 2 Save Participant as described below. The employer matching contribution for the year ended December 31, 2024 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan.

     

    7

     

     

    Abbott Laboratories Stock Retirement Plan 

    NOTES TO FINANCIAL STATEMENTS - CONTINUED 

    December 31, 2024 and 2023

     

     

     

    NOTE A - DESCRIPTION OF THE PLAN - Continued

     

    Contributions and Vesting - Continued

     

    Participants may enroll in the Freedom 2 Save program in the Plan. A Freedom 2 Save participant who makes qualified student loan repayments of at least 2% of eligible earnings may receive a Freedom 2 Save employer contribution of 5% of eligible earnings shortly after the end of the year. An enrolled Freedom 2 Save participant who makes elective deferrals to the Plan will not receive employer matching contributions each payroll period but instead may receive a true-up employer matching contribution shortly after the end of the year for any payroll period for which the participant makes elective deferrals and does not receive a Freedom 2 Save employer contribution. Freedom 2 Save employer contributions and true-up employer matching contributions are only made on behalf of Freedom 2 Save participants who meet program guidelines, and who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or terminate employment due to death or qualifying disability during such Plan year.

     

    Effective June 1, 2024, Plan participants who are not actively participating in the Abbott Laboratories Annuity Retirement Plan may receive an annual employer contribution equal to 3% of the participant’s eligible earnings, regardless of whether the participant contributes to the Plan. The 3% annual employer contribution will be made shortly after the end of the Plan year only to the eligible participants who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or who have terminated from employment during that Plan year due to death or qualifying retirement or disability during such Plan year.

     

    Employer contributions are invested according to the participant’s investment elections.

     

    Cash dividends on Abbott common shares are (1) paid in cash to the participants or beneficiaries, (2) paid to the Plan and distributed in cash to participants or beneficiaries no later than 90 days after the close of the Plan year for which paid, or (3) paid to the Plan and credited to the accounts in which shares are held, as elected by each participant or beneficiary in accordance with rules established by the administrator.

     

    On January 1, 2013, Abbott separated into two publicly traded companies – Abbott and AbbVie Inc. ("AbbVie"). The separation of Abbott and AbbVie was a tax-free distribution where Abbott shareholders received one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Participants who received AbbVie stock through this distribution may continue to hold the stock in their Plan accounts but may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan; however, participants may elect to reinvest their AbbVie dividends in AbbVie stock. If no election is made, AbbVie dividends are invested in the Plan’s default investment option.

     

    8

     

     

    Abbott Laboratories Stock Retirement Plan 

    NOTES TO FINANCIAL STATEMENTS - CONTINUED 

    December 31, 2024 and 2023

     

     

     

    NOTE A - DESCRIPTION OF THE PLAN - Continued

     

    Contributions and Vesting – Continued

     

    Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other available investment options.

     

    Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

     

       Vesting 
    Service  percentage 
    Less than two years      0%
    Two years or more  100%

     

    A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65. Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in employer contributions upon qualifying disability.

     

    Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with Abbott within a given period of time, (2) pay Plan expenses as deemed appropriate by the administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2024, forfeitures reduced Abbott’s employer contributions by approximately $5.1 million. Approximately $1.0 million and $1.0 million in forfeitures were available at the end of 2024 and 2023, respectively.

     

    Distributions and In-Service Withdrawals

     

    Following retirement, termination or death (or for some participants from merged-in plans, upon disability), participants or their beneficiaries may elect to receive a distribution in installments, in a single lump sum or in a partial lump sum. Participants may elect a direct rollover of their accounts. Also, upon termination, participants may elect to defer distribution to a future date but, after termination of employment, distribution must be made by the 1st of April following the year the participant reaches age 73 or, if earlier, the 31st of December following the year in which the participant dies. Interest, dividends and other earnings will continue to accrue on such deferred amounts.

     

    9

     

     

    Abbott Laboratories Stock Retirement Plan 

    NOTES TO FINANCIAL STATEMENTS - CONTINUED 

    December 31, 2024 and 2023

     

     

     

    NOTE A - DESCRIPTION OF THE PLAN - Continued

     

    Distributions and In-Service Withdrawals - Continued

     

    Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including Roth rollover accounts and merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, subject to certain limitations.

     

    Notes Receivable from Participants

     

    Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to IRC limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee’s anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee’s anticipated retirement date, if sooner). Repayment is made through periodic payroll deductions or by sending in payments, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

     

    10

     

     

    Abbott Laboratories Stock Retirement Plan 

    NOTES TO FINANCIAL STATEMENTS - CONTINUED 

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     

    Basis of Accounting

     

    The financial statements have been prepared using the accrual basis of accounting.

     

    Use of Estimates

     

    The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

     

    11

     

     

    Abbott Laboratories Stock Retirement Plan

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

     

    Investment Valuation

     

    The Plan offers a variety of investment options to participants. Certain investment options are structured as separately managed accounts; therefore, the Plan owns the individual investment holdings within the separately managed accounts and reflects them within the investments of the Plan.

     

    The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

     

    Common stock, mutual funds, real estate investment trusts (“REITs”) and futures contracts - Valued at the published market price per share or unit multiplied by the number of respective shares or units held.

     

    Collective trust funds and Private 40-Act mutual funds - Valued at the net asset value (“NAV”) provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

     

    Corporate debt, government debt and other - Valued at the published market price or prices obtained from independent financial services industry-recognized vendors multiplied by the number of respective units held. Prices obtained from vendors are on the basis of bid or mid evaluations in accordance to a region’s market convention, using factors which include but are not limited to market quotations, yields, maturities, and the bond’s terms and conditions. Proprietary methods are used to arrive at the evaluated price, which represent the price a dealer would pay for a security.

     

    Futures contracts

     

    One of the investment options structured as a separately managed account uses futures contracts as part of its investment strategy. A futures contract represents a commitment for the future purchase or sale of an asset or index at a specified price on a specified date. Futures contracts are exchange-traded and settle daily. Upon entering into the contracts, the investment manager of the separately managed account is required to deposit, either in cash or securities, an amount equal to a certain percentage of the notional value of the contract. Subsequent payments are then made or received by the Plan, depending on the daily fluctuation in the value of the underlying contracts.

     

    As of December 31, 2024 and 2023, the Plan held futures contracts with a notional amount of approximately $629,000 and $803,000, respectively. Notional amounts do not quantify risk or represent assets or liabilities of the Plan, but are used in the calculation of the cash settlements under the contracts. The fair value of these derivative contracts was not material at December 31, 2024 and 2023. Changes in fair value are accounted for as investment income (loss) within net appreciation in fair value of investments and totaled approximately $43,000 for the year ended December 31, 2024.

     

    12

     

     

    Abbott Laboratories Stock Retirement Plan

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

     

    Investment Valuation - Continued

     

    Short sales

    One of the investment options structured as a separately managed account utilizes short sales as part of its investment strategy. Short sales are transactions in which the separately managed account sells an investment it does not own in anticipation of a decline in value of that investment. To complete the transaction, the separately managed account must borrow the investment to make delivery to the buyer. The separately managed account is obligated to replace the investment borrowed by purchasing the investment at market price at the time of replacement. The price at such time may be more or less than the price at which the investment was sold by the separately managed account. When an investment is sold short, a decrease in the value of the investment will be recognized as a gain and an increase in the value of the investment will be recognized as a loss.

     

    The following tables summarize the basis used to measure investment assets and liabilities at fair value at December 31, 2024 and 2023 (dollars in thousands):

     

       Basis of Fair Value Measurement     
    2024  Quoted
    Prices in
    Active
    Markets
       Significant
    Other
    Observable
    Inputs
       Significant
    Unobservable
    Inputs
       Measured at
    NAV
       Total 
    Assets - Investments:                         
    Common stock  $5,066,260   $-   $                 -   $-   $5,066,260 
    Mutual funds   108,326    -    -    -    108,326 
    REITs   25,888    -    -    -    25,888 
    Collective trust funds   -    -    -    9,592,890    9,592,890 
    Corporate debt   -    235,392    -    -    235,392 
    Government debt   -    154,812    -    -    154,812 
    Private 40-Act mutual funds   -    -    -    393,035    393,035 
    Total investments, at fair value  $5,200,474   $390,204   $-   $9,985,925   $15,576,603 

     

       Basis of Fair Value Measurement     
    2024  Quoted
    Prices in
    Active
    Markets
       Significant
    Other
    Observable
    Inputs
       Significant
    Unobservable
    Inputs
       Measured at
    NAV
       Total 
    Liabilities - Investments sold short:                         
    Government debt  $-   $19,750   $                 -   $                 -   $19,750 
    Total investments sold short, at fair value  $-   $19,750   $-   $-   $19,750 

     

    13

     

     

    Abbott Laboratories Stock Retirement Plan

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

     

    Investment Valuation - Continued

     

       Basis of Fair Value Measurement     
    2023  Quoted
    Prices in
    Active
    Markets
       Significant
    Other
    Observable
    Inputs
       Significant
    Unobservable
    Inputs
       Measured at
    NAV
       Total 
    Assets - Investments:                         
    Common stock  $5,071,247   $-   $             -   $-   $5,071,247 
    Mutual funds   112,479    -    -    -    112,479 
    REITs   25,697    -    -    -    25,697 
    Collective trust funds   -    -    -    8,074,869    8,074,869 
    Corporate debt   -    269,066    -    -    269,066 
    Government debt   -    32,173    -    -    32,173 
    Private 40-Act mutual funds   -    -    -    676,472    676,472 
    Other   -    9,800    -    -    9,800 
    Total investments, at fair value  $5,209,423   $311,039   $-   $8,751,341   $14,271,803 

     

       Basis of Fair Value Measurement     
    2023  Quoted
    Prices in
    Active
    Markets
       Significant
    Other
    Observable
    Inputs
       Significant
    Unobservable
    Inputs
       Measured at
    NAV
       Total 
    Liabilities - Investments sold short:                         
    Government debt  $-   $116,452   $         -   $         -   $116,452 
    Total investments sold short, at fair value  $-   $116,452   $-   $-   $116,452 

     

    Participants are permitted to make redemptions from the Plan’s investment options on a daily basis, however, certain investments valued at NAV as a practical expedient have redemption requirements and in some cases restrictions for a Plan level redemption. The following tables provide the redemption requirements and restrictions, if any, for those investments as of December 31, 2024 and 2023. In addition, the tables provide the investment strategies for certain investments measured at NAV as a practical expedient, if that investment is a fund that does not file an annual report on Form 5500 as a direct-filing entity.

     

    14

     

     

    Abbott Laboratories Stock Retirement Plan

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

     

    Investment Valuation - Continued

     

       2024
       Fair value
    (NAV)
       Redemption
    frequency
      Redemption
    notice period
      Restrictions
    Funds filing as direct filing entity:              
    Collective trusts  $9,592,890   Daily  0 - 5 days  --
                   
    Funds not filing as direct filing entity:              
    Private 40-Act mutual funds              
    Short-term fixed income   393,035   Daily  --  Yes (a)
       $9,985,925          

     

       2023
       Fair value
    (NAV)
       Redemption
    frequency
      Redemption
    notice period
      Restrictions
    Funds filing as direct filing entity:              
    Collective trusts  $8,074,869   Daily  0 - 5 days  --
                   
    Funds not filing as direct filing entity:              
    Private 40-Act mutual funds              
    Asset-backed securities   29,900   Daily  --  Yes (a)
    Corporate fixed income   55,771   Daily  --  Yes (a)
    Inflation-indexed bonds   8,031   Daily  --  Yes (a)
    International fixed income   22,751   Daily  --  Yes (a)
    Mortgage-related securities   30,103   Daily  --  Yes (a)
    Municipal fixed income   2,573   Daily  --  Yes (a)
    Short-term fixed income   486,796   Daily  --  Yes (a)
    U.S. Government securities   40,547   Daily  --  Yes (a)
        676,472          
       $8,751,341          

     

    (a)The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of $250,000 or 1% of the respective fund’s net assets during any 90-day period for any one shareholder. In consideration of the best interests of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount in whole or in part by a distribution in kind of securities held by the respective fund in lieu of cash. It is highly unlikely that shares would ever be redeemed in kind. Redemption proceeds are ordinarily wired within three business after receipt of the redemption request, but may take up to seven days.

     

    15

     

     

    Abbott Laboratories Stock Retirement Plan

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

     

    Notes Receivable from Participants

     

    Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

     

    Income Recognition

     

    Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

     

    Contributions

     

    Contributions from Plan participants and the matching contributions from the employer are recorded in the year in which the employee contributions are withheld from compensation.  Freedom 2 Save employer contributions, true-up employer matching contributions, and the 3% annual employer contribution are accrued in the year in which they are earned.

     

    Administrative Expenses

     

    Participants are charged transaction fees for loan processing, which are included in other expenses and commissions on purchases and sales of Abbott shares and sales of AbbVie stock, which are included in net appreciation in fair value of investments. Investment fees for mutual funds, REITs, collective trusts, and managed accounts are charged against the net assets of the respective fund and are also included in net appreciation in fair value of investments. Abbott pays other recordkeeping and administration fees, where applicable. Expenses that are paid by Abbott are excluded from these financial statements.

     

    Payment of Benefits

     

    Benefits are recorded when paid.

     

    16

     

     

    Abbott Laboratories Stock Retirement Plan

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE C - INVESTMENTS

     

    Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

     

    A summary of Abbott common share data as of December 31, 2024 and 2023 is presented below:

     

       2024   2023 
    Abbott common shares, 24,199,951 and 26,051,349 shares, respectively (dollars in thousands)  $2,737,256   $2,867,472 
    Market value per share  $113.11   $110.07 

     

    NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

     

    The Plan holds units of collective trust funds managed by the Trustee and shares of the Trustee’s common stock. A significant portion of the Plan’s assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2024, the Plan received $55.8 million in common stock dividends from Abbott.

     

    Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

     

    NOTE E - PLAN TERMINATION

     

    The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the Trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

     

    17

     

     

    Abbott Laboratories Stock Retirement Plan

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE F - TAX STATUS

     

    The Internal Revenue Service (“IRS”) has determined and informed Abbott by a letter dated April 13, 2022, that the Plan and related Trust are designed in accordance with applicable sections of the IRC. The Plan has been amended since the applicable date of the determination letter. However, the Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable requirements of the IRC.

     

    Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS or other applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2024 and 2023, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions. There are currently no audits in progress.

     

    NOTE G - RISKS AND UNCERTAINTIES

     

    In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

     

    NOTE H - SUBSEQUENT EVENTS

     

    Management of the Plan has evaluated subsequent events from December 31, 2024 through the date these financial statements were issued. Other than described below, management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

     

    Effective January 1, 2025, forfeitures will be used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, and (2) reduce future employer contributions if terminated participants do not return to service within the given period of time.

     

    18

     

     

    SUPPLEMENTAL SCHEDULE

     

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
      Common stock - employer securities        
    *  ABBOTT LABORATORIES, common shares        $2,737,256 
                   
       Common stock           
       10X GENOMICS INC CL A         16 
       5TH 3RD BANCORP COM         940 
       ABBVIE INC.         2,068,558 
       ACADIA HEALTHCARE CO INC COM         119 
       ACUITY BRANDS INC COM         296 
       ADT INC DEL COM         75 
       ADVANCE AUTO PTS INC COM         92 
       ADVANCED DRAIN SYS INC DEL COM         166 
       AECOM         470 
       AES CORP COM         300 
       AFFILIATED MANAGERS GROUP INC COM STK         178 
       AFFIRM HLDGS INC CL A         519 
       AFLAC INC COM         1,899 
       AGCO CORP COM         191 
       AGILENT TECHNOLOGIES INC COM         1,269 
       AIR LEASE CORP CL A         165 
       AKAMAI TECHNOLOGIES INC COM STK         468 
       ALASKA AIR GROUP INC COM         267 
       ALBEMARLE CORP COM         332 
       ALBERTSONS COS INC CL A         270 
       ALIGN TECHNOLOGY INC COM         213 
       ALLEGION PLC COMMON STOCK         376 
       ALLEGRO MICROSYSTEMS INC DEL COM         88 
       ALLIANT ENERGY CORP COM         498 
       ALLISON TRANSMISSION HOLDING         307 
       ALLSTATE CORP COM         1,406 
       ALLY FINL INC COM         281 
       ALNYLAM PHARMACEUTICALS INC COM         112 
       AMCOR PLC         445 
       AMDOCS         313 
       AMEDISYS INC COM         95 
       AMENTUM HLDGS INC COM         90 
       AMER FINL GROUP INC OH COM STK         323 
       AMER SPORTS INC COM         53 
       AMEREN CORP COM         781 
       AMERICAN AIRLINES INC COM         348 
       AMERICAN WTR WKS CO INC NEW COM         799 
       AMERIPRISE FINL INC COM         150 
       AMETEK INC NEW COM         1,369 
       AMKOR TECHNOLOGY INC COM         95 
       ANSYS INC COM         968 
       ANTERO MIDSTREAM CORPORATION         103 
       ANTERO RES CORP COM         334 
       APA CORP COM         275 
       API GROUP CORPORATION COM         269 
       APTARGROUP INC COM         340 
       APTIV PLC NEW ORD         467 
       ARAMARK COM         321 
       ARCH CAPITAL GROUP COM STK         1,096 
       ARCHER-DANIELS-MIDLAND CO COM         793 
       ARMSTRONG WORLD INDS INC NEW COM STK         134 
       ARROW ELECTR INC COM         195 
       ASHLAND INC COM         114 

     

    19

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
      Common stock - continued         
       ASPEN         220 
       ASSURANT INC COM         365 
       ASSURED GUARANTY LTD COMMON STK         149 
       ASTERA LABS INC COM         447 
       ATI INC COM         223 
       ATMOS ENERGY CORP COM         709 
       AUTONATION INC COM         142 
       AVANGRID         - 
       AVANTOR INC COM         470 
       AVERY DENNISON CORP COM         307 
       AVIS BUDGET GROUP INC COM STK         27 
       AVNET INC COM         149 
       AXALTA COATING SYSTEMS LTD COM         245 
       AXIS CAPITAL HOLDINGS LTD COM         224 
       AZEK CO INC CL A         67 
       AZENTA INC COM         79 
       BAKER HUGHES CO         1,347 
       BALL CORP COM         536 
       BANK NEW YORK MELLON CORP COM STK         1,868 
       BANK OZK COM         156 
       BATH & BODY WORKS INC COM         280 
       BAXTER INTL INC COM         489 
       BELLRING BRANDS INC COM         319 
       BERKLEY W R CORP COM         566 
       BERRY GLOBAL GROUP INC         244 
       BEST BUY INC COM STK         608 
       BILL HOLDINGS INC COM         211 
       BIO RAD LABORATORIES INC CL A         204 
       BIOGEN INC COMMON STOCK         733 
       BIOMARIN PHARMACEUTICAL INC COM         408 
       BIO-TECHNE CORP COM         368 
       BIRKENSTOCK HOLDING PLC COM NPV         73 
       BJS WHSL CLUB HLDGS INC COM         388 
       BLOCK H & R INC COM         195 
       BLOCK INC         898 
       BOK FINL CORP COM NEW         79 
       BORG WARNER INC COM         227 
       BOSTON BEER INC CL A         68 
       BOYD GAMING CORP COM         151 
       BRIGHT HORIZONS FA COM         179 
       BRIGHTHOUSE FINL INC COM         95 
       BROADRIDGE FINL SOLUTIONS INC COM STK         76 
       BROOKFIELD RENEWABLE CORP NEW CL A         123 
       BROWN & BROWN INC COM         449 
       BROWN FORMAN CORP CL A         59 
       BROWN-FORMAN INC CL B NON-VTG COM         217 
       BRUKER CORP         77 
       BRUNSWICK CORP COM         139 
       BUILDERS FIRSTSOURCE INC COM STK         490 
       BUNGE GLOBAL SA F COMMON STOCK         355 
       BWX TECHNOLOGIES INC COM         266 
       C H ROBINSON WORLDWIDE INC COM NEW         395 
       CACI INTL INC CL A         293 
       CAESARS ENTMT INC NEW COM         232 
       CAPRI HOLDINGS LTD COM NPV         79 
       CARDINAL HLTH INC         384 

     

    20

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       CARLISLE COMPANIES INC COM         474 
       CARLYLE GROUP INC COM         364 
       CARMAX INC COM         387 
       CARNIVAL CORP COM PAIRED         841 
       CARTER INC F         63 
       CARVANA CO CL A         471 
       CASEYS GEN STORES INC COM         399 
       CBOE GLOBAL MARKETS INC         678 
       CBRE GROUP INC CL A CL A         1,321 
       CCC INTELLIGENT SOLUTIONS HLDGS INC COM         174 
       CDW CORP COM         382 
       CELANESE CORP DEL COM STK         185 
       CENTENE CORP DEL COM         1,006 
       CENTERPOINT ENERGY INC COM         674 
       CERTARA INC COM         42 
       CF INDS HLDGS INC COM         487 
       CHARLES RIV LABORATORIES INTL INC COM         310 
       CHARTER COMMUNICATIONS INC NEW CL A CL A         1,058 
       CHEMED CORP NEW COM         233 
       CHEMOURS CO COM         77 
       CHENIERE ENERGY INC COM NEW         772 
       CHOICE HOTELS INTL INC COM         20 
       CHORD ENERGY CORPORATION COM         237 
       CHURCH & DWIGHT INC COM         840 
       CIENA CORP COM NEW         401 
       CIN FNCL CORP COM         724 
       CIRRUS LOGIC INC COM         176 
       CITIZENS FINL GROUP INC COM         643 
       CIVITAS RES INC COM         107 
       CLARIVATE PLC         68 
       CLEAN HBRS INC COM         385 
       CLEARWAY ENERGY INC CL A CL A         28 
       CLEARWAY ENERGY INC CL C CL C         70 
       CLEVELAND CLIFFS         100 
       CMS ENERGY CORP COM         654 
       CNA FNCL CORP COM         34 
       CNH INDUSTRIAL NV COM STK         325 
       COCA-COLA CONSOLIDATED INC COM         251 
       COGNEX CORP COM         192 
       COGNIZANT TECH SOLUTIONS CORP CL A         1,259 
       COHERENT CORP COM         389 
       COINBASE GLOBAL INC COM CL A         265 
       COLUMBIA BKG SYS INC COM         185 
       COLUMBIA SPORTSWEAR CO COM         90 
       COM ALCOA CORPORATION COM         307 
       COMERICA INC COM         270 
       COMM BANCSHARES INC COM         252 
       CONAGRA BRANDS INC COM USD5         435 
       CONCENTRIX CORP         67 
       CONS EDISON INC COM         1,017 
       CORE & MAIN INC COM CL A COM CL A         110 
       COREBRIDGE FINL INC COM         291 
       CORNING INC COM         1,198 
       CORTEVA INC COM         1,311 
       COSTAR GROUP INC COM         956 
       COTERRA ENERGY INC COM         612 

     

    21

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       COTY INC COM CL A COM CL A         87 
       CRANE CO NEW COM         244 
       CRANE NXT CO COM         94 
       CREDIT ACCEP CORP MICH COM         21 
       CROCS INC COM         169 
       CROWN HLDGS INC COM         318 
       CULLEN / FROST BANKERS INC COM         260 
       CUMMINS INC         1,567 
       CURTISS WRIGHT CORP COM         445 
       D R HORTON INC COM         1,342 
       DARDEN RESTAURANTS INC COM         338 
       DARLING INGREDIENTS INC COMSTK         176 
       DAYFORCE INC         322 
       DELTA AIR LINES INC DEL COM NEW COM NEW         1,282 
       DENTSPLY SIRONA INC COM         126 
       DEVON ENERGY CORP NEW COM         671 
       DIAMONDBACK ENERGY INC COM         1,017 
       DICKS SPORTING GOODS INC OC-COM OC-COM         383 
       DILLARDS INC CL A COM         44 
       DISCOVER FINL SVCS COM STK         1,425 
       DOLBY LABORATORIES INC CL A COM STK         150 
       DOLLAR GEN CORP NEW COM         548 
       DOLLAR TREE INC COM STK         499 
       DOMINOS PIZZA INC COM         313 
       DONALDSON INC COM         266 
       DOUBLEVERIFY HLDGS INC COM         40 
       DOVER CORP COM         846 
       DOW INC         929 
       DOXIMITY INC COM         199 
       DROPBOX INC CL A CL A         163 
       DT MIDSTREAM INC COM         317 
       DTE ENERGY CO COM         821 
       DUN & BRADSTREET HLDGS INC COM         124 
       DUPONT DE NEMOURS INC COMMON STOCK         1,049 
       DUTCH BROS INC CL A CL A         114 
       DXC TECHNOLOGY CO COM         118 
       EAGLE MATLS INC COM         66 
       EAST WEST BANCORP INC COM         434 
       EASTMAN CHEM CO COM         351 
       EBAY INC COM         975 
       EDISON INTL COM         1,000 
       ELANCO ANIMAL HEALTH INC COM         196 
       ELECTR ARTS COM         1,272 
       ELEMENT SOLUTION INC COM         187 
       EMCOR GROUP INC COM         411 
       ENCOMPASS HEALTH CORP COM         301 
       ENOVIS CORPORATION  COM         80 
       ENTERGY CORP NEW COM         1,063 
       ENVISTA HLDGS CORP COM         109 
       EPAM SYS INC COM STK         394 
       EQT CORP COM         838 
       EQUIFAX INC COM         823 
       ESAB CORPORATION COM         223 
       ESSENTIAL UTILS INC COM         301 
       ETSY INC COM         68 
       EURONET WORLDWIDE INC COM         143 

     

    22

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       EVERCORE INC         327 
       EVEREST GROUP LTD         430 
       EVERGY INC COM NPV         452 
       EVERSOURCE ENERGY COM         676 
       EVERUS CONSTR GROUP INC COM         110 
       EXACT SCIENCES CORP COM         204 
       EXELIXIS INC COM STK         51 
       EXELON CORP COM         1,239 
       EXPAND ENERGY CORP         755 
       EXPEDITORS INTL WASH INC COM         431 
       F N B CORP PA COM         172 
       F5 INC COM STK NPV         483 
       FACTSET RESH SYS INC COM STK         389 
       FAIR ISAAC CORPORATION COM         239 
       FASTENAL CO COM         213 
       FERGUSON ENTERPRISES INC         1,078 
       FIDELITY NATL FINL INC         479 
       FIDELITY NATL INFORMATION SVCS INC COM  STK         1,451 
       FIRST AMERN FINL CORP COM STK         205 
       FIRST CTZNS BANCSHARES INC CL A CL A         833 
       FIRST HAWAIIAN INC COM         108 
       FIRST HORIZON  CORPORATION COM         353 
       FIRST SOLAR INC COM         618 
       FIRSTENERGY CORP COM         754 
       FIVE BELOW INC COM         38 
       FLOOR & DECOR HLDGS INC CL A         219 
       FLOWERS FOODS INC COM         126 
       FLOWSERVE CORP COM         248 
       FMC CORP COM (NEW)         199 
       FORTIVE CORP COM MON STOCK         855 
       FORTREA HLDGS INC COM         49 
       FORTUNE BRANDS INNOVATIONS INC         277 
       FOX CORP CL A CL A         352 
       FOX CORP CL B CL B         201 
       FRESHPET INC COM         154 
       FRKLN RES INC COM         191 
       FRONTIER COMMUNICATIONS PARENT INC  COM NPV         280 
       FTI CONSULTING INC COM         221 
       GALLAGHER ARTHUR J & CO COM         2,137 
       GAMESTOP CORP NEW CL A         405 
       GAP INC COM         158 
       GARMIN LTD COMMON STOCK         1,051 
       GATES INDL CORP PL COM         160 
       GE HEALTHCARE TECHNOLOGIES INC COM         1,060 
       GEN DIGITAL INC COM         490 
       GENERAC HLDGS INC COM STK         153 
       GENERAL MILLS INC COM         1,172 
       GENPACT LIMITED COM STK         245 
       GENTEX CORP COM         218 
       GENUINE PARTS CO COM         534 
       GLOBAL PMTS INC COM         938 
       GLOBALFOUNDRIES INC         139 
       GLOBANT SA USD1.20         73 
       GLOBE LIFE INC COM         326 
       GLOBUS MED INC CL A NEW COM STK         304 
       GRACO INC COM         464 

     

    23

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       GRAIL INC COM         15 
       GRAINGER W W INC COM         198 
       GRAND CANYON ED INC COM STK         106 
       GRAPHIC PACKAGING HLDG CO COM STK         265 
       GROCERY OUTLET HLDG CORP COM         49 
       GUIDEWIRE SOFTWARE INC COM         247 
       GXO LOGISTICS INC COM         168 
       HALLIBURTON CO COM         789 
       HANOVER INS GROUP INC COM         181 
       HARLEY DAVIDSON COM         117 
       HASBRO INC COM         32 
       HASHICORP INC         35 
       HAYWARD HLDGS INC COM         71 
       HENRY SCHEIN INC COMMON STOCK         287 
       HERSHEY COMPANY COM STK         699 
       HESS CORP COM STK         432 
       HEWLETT PACKARD ENTERPRISE CO COM         911 
       HEXCEL CORP NEW COM         168 
       HF SINCLAIR CORPORATION COM         178 
       HILTON WORLDWIDE HLDGS INC COM NEW         950 
       HOLOGIC INC COM         542 
       HORMEL FOODS CORP COM         299 
       HOULIHAN LOKEY INC CL A CL A         273 
       HOWARD HUGHES HLDGS INC COM         78 
       HOWMET AEROSPACE INC COM         1,369 
       HP INC COM         784 
       HUBBELL INC COM         738 
       HUMANA INC COM         1,007 
       HUNT J B TRANS SVCS INC COM         455 
       HUNTINGTON BANCSHARES INC COM         772 
       HUNTINGTON INGALLS INDS INC COM         242 
       HUNTSMAN CORP COM STK         96 
       HYATT HOTELS CORP COM CL A COM CL A         181 
       IAC INC COM NEW         105 
       IDACORP INC COM         191 
       IDEX CORP COM         521 
       ILLUMINA INC COM         700 
       INCYTE CORP COM         340 
       INFORMATICA INC CL A CL A         69 
       INGERSOLL RAND INC COM         1,201 
       INGRAM MICRO HLDG CORP COM         8 
       INGREDION INC COM         297 
       INTERACTIVE BROKERS GROUP INC CL COM         614 
       INTERPUBLIC GROUP COMPANIES INC COM         343 
       INTL FLAVORS & FRAGRANCES INC COM         711 
       INTL PAPER CO COM         613 
       INVESCO LTD COM STK USD0.20         210 
       IONIS PHARMACEUTICALS INC COM         12 
       IPG PHOTONICS CORP COM         65 
       IQVIA HLDGS INC COM         1,033 
       IRIDIUM COMMUNICATIONS INC COM STK         97 
       ITT INC COM         387 
       JABIL INC COM USD0.001         480 
       JACK HENRY & ASSOC INC COM         418 
       JACOBS SOLUTIONS INC COM         542 
       JANUS HENDERSON GROUP PLC         179 

     

    24

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       JAZZ PHARMACEUTICALS PLC COM         244 
       JEFFERIES FINL GROUP INC COM         323 
       JONES LANG LASALLE INC COM STK         272 
       JUNIPER NETWORKS INC COM         401 
       KBR INC COM         232 
       KELLANOVA COM         698 
       KEMPER CORP DEL COM         132 
       KENVUE INC COM         1,345 
       KEYCORP NEW COM         522 
       KEYSIGHT TECHNOLOGIES INC COM         921 
       KINDER MORGAN INC DEL COM         1,747 
       KIRBY CORP COM         202 
       KNIGHT-SWIFT TRANSN HLDGS INC CL A         272 
       KOHLS CORP COM         51 
       KROGER CO COM         1,335 
       KYNDRYL HLDGS INC COM         259 
       L3HARRIS TECHNOLOGIES INC COM         1,310 
       LABCORP HLDGS INC COM         634 
       LAMB WESTON HLDGS INC COM USD5         212 
       LANDSTAR SYS INC COM         199 
       LATTICE SEMICONDUCTOR CORP COM         34 
       LEAR CORP COM NEW COM NEW         168 
       LEGGETT & PLATT INC COM         42 
       LEIDOS HLDGS INC COM         630 
       LENNAR CORP CL A CL A         1,056 
       LENNAR CORP CL B CL B         47 
       LIBERTY BROADBAND CORP COM SER A COM SERA         29 
       LIBERTY BROADBAND CORP COM SER C COM SERC         206 
       LIBERTY GLOBAL LTD. COM CLASS C         65 
       LIBERTY GLOBAL LTD. COMMON STOCK         70 
       LIBERTY MEDIA CORP DEL COM LIBERTY   FORMULA ONE SER A         40 
       LIBERTY MEDIA CORP DEL COM LIBERTY   FORMULA ONE SER C         413 
       LIBERTY MEDIA CORP DEL COM LIBERTY LIVE SER A         43 
       LIBERTY MEDIA CORP DEL COM LIBERTY LIVE SER C         104 
       LINCOLN ELEC HLDGS INC COM         245 
       LINCOLN NATL CORP COM         177 
       LITHIA MTRS INC COM CL A         308 
       LITTELFUSE INC COM         189 
       LKQ CORP COM LKQ CORP         313 
       LOAR HOLDINGS INC COM         7 
       LOEWS CORP COM         498 
       LOUISIANA-PACIFIC CORP COM         64 
       LUCID GROUP INC COM         98 
       LUMENTUM HLDGS INC COM         188 
       LYFT INC CL A CL A         48 
       LYONDELLBASELL IND N V COM         636 
       M & T BK CORP COM         1,028 
       MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC COM STK         238 
       MACYS INC COM STK         152 
       MADISON SQUARE GARDEN SPORTS CORP         127 
       MANPOWERGROUP INC         89 
       MAPLEBEAR INC COM         227 
       MARKEL GROUP INC         549 
       MARKETAXESS HLDGS INC COM STK         275 
       MARRIOTT VACATIONS WORLDWIDE CORP COM         103 
       MARTIN MARIETTA MATLS INC COM         983 

     

    25

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       MASCO CORP COM         515 
       MASIMO CORP COM STK         113 
       MASTEC INC COM         281 
       MATADOR RES CO COM         201 
       MATCH GROUP INC NEW COM         277 
       MATTEL INC COM STOCK         197 
       MC CORMICK & CO INC COM NON-VTG         632 
       MDU RES GROUP INC COM         120 
       METTLER-TOLEDO INTL INC COM         849 
       MGIC INVT CORP WIS COM         201 
       MGM RESORTS INTERNATIONAL COM         261 
       MICROCHIP TECHNOLOGY INC COM         1,000 
       MICROSTRATEGY INC CL A NEW CL A NEW         1,470 
       MIDDLEBY CORP COM         237 
       MKS INSTRS INC COM         216 
       MLP VIPER ENERGY INC         117 
       MOHAWK INDS INC COM         205 
       MOLINA HEALTHCARE INC COM         201 
       MOLSON COORS BEVERAGE COMPANY COM  CLASS B         322 
       MOSAIC CO/THE         259 
       MP MATERIALS CORP COM         67 
       MSA SAFETY INC COM         202 
       MSC INDL DIRECT INC CL A COM         112 
       MSCI INC COM         632 
       NASDAQ INC         1,048 
       NATL FUEL GAS CO COM         182 
       NCINO INC NEW COM         35 
       NETAPP INC COM STK         434 
       NEW FORTRESS INC CL A         19 
       NEW YORK TIMES CO CL A         275 
       NEWELL BRANDS INC COM         136 
       NEWMARKET CORP COM         117 
       NEWS CORP COM CL A         345 
       NEWS CORP COM CL B         113 
       NEXSTAR MEDIA GROUP INC COMMON STOCK         97 
       NISOURCE INC COM         563 
       NORDSON CORP COM         390 
       NORDSTROM INC COM         79 
    *  NORTHERN TR CORP COM         661 
       NOV INC COM         186 
       NRG ENERGY INC COM NEW         361 
       NUCOR CORP COM         910 
       NUTANIX INC CL A CL A         361 
       NVENT ELECTRIC PLC COM         370 
       NVR INC COM STK         777 
       OGE ENERGY CORP COM         270 
       OKTA INC CL A CL A         232 
       OLD REPUBLIC INTERNATIONAL CORP COM STK         280 
       OLIN CORP COM         130 
       OLLIES BARGAIN OUTLET HLDGS INC COM         220 
       OMNICOM GROUP INC COM         548 
       ON SEMICONDUCTOR CORP COM         881 
       ONEMAIN HLDGS INC COM         194 
       ONEOK INC COM STK         1,927 
       ONTO INNOVATION INC         200 
       ORGANON & CO COM         126 

     

    26

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       OSHKOSH CORPORATION         204 
       OTIS WORLDWIDE CORP COM         1,217 
       OVINTIV INC COM         351 
       OWENS CORNING NEW COM STK         483 
       PACKAGING CORP AMER COM         656 
       PARAMOUNT GLOBAL COM CL A         7 
       PARAMOUNT GLOBAL COM CL B         204 
       PARSONS CORP DEL COM         139 
       PAYCHEX INC COM         951 
       PAYCOM SOFTWARE INC COM         127 
       PAYCOR HCM INC COM         45 
       PENN ENTERTAINMENT INC         98 
       PENSKE AUTOMOTIVE GROUP INC COM STK         92 
       PENTAIR PLC COM         546 
       PERFORMANCE FOOD GROUP CO COM         364 
       PERMIAN RES CORP CL A         243 
       PERRIGO COMPANY LIMITED COM         114 
       PG& E CORP COM         1,419 
       PILGRIMS PRIDE CORP         56 
       PINNACLE FINL PARTNERS INC COM         285 
       PINNACLE W. CAP CORP COM         317 
       PLANET FITNESS INC CL A CL A         126 
       PLAYTIKA HLDG CORP COM         16 
       POLARIS INC         97 
       POPULAR INC COM NEW         198 
       POST HLDGS INC COM STK         179 
       PPG IND INC COM         909 
       PPL CORP COM         788 
       PREMIER INC CL A CL A         67 
       PRIMERICA INC COM         301 
       PRINCIPAL FINL GROUP INC COM STK         578 
       PROSPERITY BANCSHARES INC COM         222 
       PRUDENTIAL FINL INC COM         1,402 
       PTC INC COM         281 
       PUB SERVICE ENTERPRISE GROUP INC COM         1,386 
       PULTE GROUP INC         731 
       PURE STORAGE INC CL A CL A         79 
       PVH CORP COM         193 
       QIAGEN NV ORD         327 
       QORVO INC COM         218 
       QUANTA SVCS INC COM         1,048 
       QUANTUMSCAPE CORP  COM CL A         61 
       QUEST DIAGNOSTICS INC COM         551 
       QUIDELORTHO CORPORATION         91 
       RALPH LAUREN CORP CL A CL A         300 
       RANGE RES CORP COM         281 
       RAYMOND JAMES FNCL INC COM STK         940 
       RB GLOBAL INC COM NPV         543 
       RBC BEARINGS INC COM         279 
       REGAL REXNORD CORPORATION COM STK         338 
       REGIONS FINL CORP NEW COM         710 
       REINSURANCE GROUP AMER INC COM NEW STK         461 
       RELIANCE INC COM NPV         476 
       RENAISSANCE RE HLDGS LTD COM         420 
       REPLIGEN CORP COM STK         226 
       RESMED INC COM         795 

     

    27

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       REVVITY INC         451 
       REYNOLDS CONSUMER PRODS INC COM         48 
       RH COM         155 
       RIVIAN AUTOMOTIVE INC         365 
       RLI CORP COM         211 
       ROBERT HALF INC COM         234 
       ROBINHOOD MKTS INC COM CL A         824 
       ROCKET COS INC CL A CL A         51 
       ROCKWELL AUTOMATION         978 
       ROIVANT SCIENCES LTD COM         165 
       ROKU INC COM CL A COM CL A         263 
       ROSS STORES INC COM         1,246 
       ROYAL CARIBBEAN GROUP COM STK         1,175 
       ROYAL GOLD INC COM STK         285 
       ROYALTY PHARMA PLC COM CLASS A         327 
       RPM INTL INC         398 
       RYDER SYS INC COM         214 
       S.W. AIRL CO COM         661 
       SAIA INC COM STK         165 
       SCHNEIDER NATL INC WIS CL B CL B         44 
       SCIENCE APPLICATIONS INTL CORP NEW COM         181 
       SCOTTS MIRACLE-GRO CLASS'A'COM NPV         93 
       SEABOARD CORP DEL COM         19 
       SEALED AIR CORP NEW COM STK         153 
       SEAPORT ENTMT GROUP INC COM         7 
       SEI INVTS CO COM         272 
       SENSATA TECHNOLOGIES B V HOLDING         135 
       SENTINELONE INC CL A COM CL A COM         171 
       SERVICE CORP INTL COM         369 
       SHARKNINJA COM         170 
       SILGAN HLDGS INC COM         142 
       SIMPSON MFG INC COM         210 
       SIRIUS XM HLDGS INC NEW COM         161 
       SITEONE LANDSCAPE SUPPLY INC COM         122 
       SKECHERS U S A INC CL A         266 
       SKYWORKS SOLUTIONS INC COM         468 
       SLM CORP COM         191 
       SMITH A O CORP COM         266 
       SMUCKER J M CO COM NEW         373 
       SMURFIT WESTROCK LTD         916 
       SNAP-ON INC COM         578 
       SOFI TECHNOLOGIES INC COM         451 
       SOLVENTUM CORP COM COM         301 
       SONOCO PROD CO COM         157 
       SOTERA HEALTH CO COM         68 
       SPECTRUM BRANDS HLDGS INC COM         75 
       SPIRIT AEROSYSTEMS HLDGS INC CL A         114 
       SS&C TECHNOLOGIES HLDGS INC COM         535 
       STANDARDAERO INC. COM         38 
       STANLEY BLACK & DECKER INC COM         406 
       STATE STR CORP COM         946 
       STEEL DYNAMICS INC COM         545 
       STERIS PLC ORD         666 
       STIFEL FINL CORP COM         347 
       SYNCHRONY FINL COM         832 
       SYNOVUS FINL CORP COM NEW COM NEW         242 

     

    28

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       SYSCO CORP COM         469 
       T ROWE PRICE GROUP INC         816 
       TAKE-TWO INTERACTIVE SOFTWARE INC         1,044 
       TAPESTRY INC COM         499 
       TD SYNNEX CORPORATION COM         291 
       TECHNIPFMC PLC COM         403 
       TELEDYNE TECHNOLOGIES INC COM         706 
       TELEFLEX INC COM         272 
       TENET HEALTHCARE CORP COM NEW .         395 
       TERADYNE INC COM         58 
       TETRA TECH INC NEW COM         274 
       TEXTRON INC COM         470 
       TFS FINL CORP COM STK         20 
       THE CAMPBELLS COMPANY         264 
       THE COOPER COMPANIES, INC.         590 
       THE HARTFORD INSURANCE GROUP INC COM         1,042 
       THOR INDS INC COM STK         160 
       TIMKEN CO COM         152 
       TKO GROUP HLDGS INC COM         318 
       TOLL BROS INC COM         417 
       TOPBUILD CORP COM         284 
       TORO CO COM         270 
       TPG PARTNERS LLC CL A COM         131 
       TRADEWEB MKTS INC CL A CL A         303 
       TRANSUNION COM         558 
       TRAVEL + LEISURE CO COM         109 
       TRIMBLE INC COM TRIMBLE INC         566 
       TRIPADVISOR INC COM         50 
       TRUMP MEDIA & TECHNOLOGY GROUP CORP         31 
       TWILIO INC CL A CL A         436 
       TYLER TECHNOLOGIES INC COM STK         121 
       TYSON FOODS INC CL A COM (DELAWARE)         531 
       UBIQUITI INC COM         25 
       UGI CORP NEW COM         200 
       U-HAUL HOLDING  COMPANY         119 
       U-HAUL HOLDING  COMPANY         10 
       UIPATH INC CL A CL A         25 
       ULTA BEAUTY INC         91 
       UNDER ARMOR INC CL A         53 
       UNDER ARMOUR INC CL C COM         45 
       UNITED AIRLINES HOLDINGS INC COM         1,046 
       UNITED RENTALS INC COM         1,150 
       UNITED STS STL CORP NEW COM         249 
       UNITED THERAPEUTICS CORP DEL COM STK         507 
       UNITY SOFTWARE INC COM         124 
       UNIVERSAL DISPLAY CORP COM         111 
       UNUM GROUP         436 
       UNVL HEALTH SERVICES INC CL B COM         338 
       US FOODS HLDG CORP COM         509 
       UWM HLDGS CORP COM CL A         6 
       V F CORP COM         247 
       VAIL RESORTS INC COM         37 
       VALMONT INDS INC COM         201 
       VERALTO CORP COM         455 
       VERISIGN INC COM         531 
       VESTIS CORP COM         66 

     

    29

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Common stock - continued           
       VIATRIS INC         486 
       VIRTU FINL INC CL A CL A         94 
       VONTIER CORP COM         180 
       VOYA FINL INC COM         223 
       VULCAN MATERIALS CO COM         831 
       WABTEC CORP COM         1,063 
       WALGREENS BOOTS ALLIANCE INC COM         220 
       WARNER BROS DISCOVERY INC         844 
       WATERS CORP COM         281 
       WATSCO INC COM         539 
       WAYFAIR INC CL A CL A         139 
       WEBSTER FNCL CORP WATERBURY CONN COM         310 
       WEC ENERGY GROUP INC COM         979 
       WENDYS CO COM         46 
       WESCO INTL INC COM         250 
       WEST PHARMACEUTICAL SVCS INC COM         308 
       WESTERN ALLIANCE BANCORPORATION COM         295 
       WESTERN UNION CO         97 
       WESTLAKE CORPORATION COM         126 
       WESTN DIGITAL CORP COM         678 
       WEX INC COM         207 
       WHIRLPOOL CORP COM         199 
       WHITE MOUNTAINS INSURANCE GROUP COM STOCK         160 
       WILLIAMS CO INC COM         2,167 
       WILLIAMS SONOMA INC COM         311 
       WILLIS TOWERS WATSON PLC COM         1,038 
       WILLSCOT HOLDINGS CORPORATION COM         139 
       WINTRUST FINL CORP COM         267 
       WOLFSPEED INC COM         27 
       WOODWARD INC COM         322 
       WYNDHAM HOTELS & RESORTS INC COM         229 
       WYNN RESORTS LTD COM         268 
       XCEL ENERGY INC COM         1,277 
       XP INC COM  CLASS A         143 
       XYLEM INC COM         922 
       YETI HLDGS INC COM         76 
       YUM BRANDS INC COM         766 
       ZEBRA TECHNOLOGIES CORP CL A         511 
       ZILLOW GROUP INC COM         106 
       ZILLOW GROUP INC COM CLASS C         380 
       ZIMMER BIOMET HLDGS INC COM         688 
       ZIONS BANCORPORATION N A         259 
       ZOOM COMMUNICATIONS INC         708 
       ZOOMINFO TECHNOLOGIES INC COM         104 
       Total Common stock         5,066,260 
                   
       Mutual fund           
       PIMCO ALL ASSET FUND         108,326 
                   
       REITs           
       1ST INDL RLTY TR INC COM         218 
       AGNC INVT CORP COM         246 
       AGREE RLTY CORP COM         248 
       ALEXANDRIA REAL ESTATE EQUITIES INC COM         556 
       AMERICAN HOMES 4 RENT COMMON STOCK         415 
       AMERICOLD RLTY TR INC COM         200 

     

    30

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       REITs - continued           
       ANNALY CAPITAL MANAGEMENT INC         336 
       AVALONBAY CMNTYS REIT         1,027 
       BRIXMOR PPTY GROUP INC COM         274 
       BXP INC         384 
       CAMDEN PPTY TR SH BEN INT         395 
       COUSINS PPTYS INC         162 
       CROWN CASTLE INC COM         1,299 
       CUBESMART         315 
       DIGITAL RLTY TR INC COM         1,933 
       EASTGROUP PPTYS INC REIT         259 
       EPR PPTYS COM SH BEN INT COM SH BEN INT         109 
       EQTY LIFESTYLE PPTYS INC REIT         414 
       EQTY RESDNTL         892 
       ESSEX PPTY TR REIT         600 
       EXTRA SPACE STORAGE INC COM         1,029 
       FEDERAL RLTY INVT TR  COM         311 
       GAMING & LEISURE PPTYS INC COM         412 
       HEALTHCARE REALTY TRUST INC COM         196 
       HEALTHPEAK OP LLC         466 
       HIGHWOODS PPTYS INC COM         105 
       HOST HOTELS & RESORTS INC REIT         402 
       INVITATION HOMES INC COM         643 
       IRON MTN INC NEW COM         432 
       KILROY RLTY CORP COM         156 
       KIMCO REALTY CORPORATION         507 
       LAMAR ADVERTISING CO NEW CL A CL A         261 
       LINEAGE INC COM         119 
       MEDICAL PPTYS TR INC COM REIT         77 
       MID-AMER APT CMNTYS INC COM         591 
       NATIONAL STORAGE AFFILIATES TR COM SHS         87 
       NNN REIT INC         251 
       OMEGA HEALTHCARE INVS INC REIT         336 
       PARK HOTELS & RESORTS INC COM         94 
       RAYONIER INC REIT         132 
       REALTY INCOME CORP COM         1,531 
       REGENCY CTRS CORP COM         439 
       REXFORD INDL RLTY INC COM         280 
       RITHM CAPITAL CORP         184 
       SBA COMMUNICATIONS CORP         720 
       SIMON PROPERTY GROUP INC COM         1,364 
       STAG INDL INC COM         201 
       STARWOOD PROPERTY TRUST INC COM REIT         195 
       SUN COMMUNITIES INC COM         499 
       UDR INC COM STK         469 
       VENTAS INC REIT         811 
       VICI PPTYS INC COM         1,000 
       VORNADO RLTY TR COM         242 
       W P CAREY INC COM         389 
       WEYERHAEUSER CO COM         675 
       Total REITs         25,888 
                   
       Collective trust funds           
       BLACKROCK INTERNATIONAL MULTI CAP EQUITY FUND         103,319 
       CAPITAL GROUP EUROPACIFIC GROWTH TRUST         349,968 
       CAPITAL GROUP GROWTH FUND OF AMERICA TRUST         1,349,967 
       CAPITAL GROUP WASHINGTON MUTUAL INVESTORS TRUST         396,199 

     

    31

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Collective trust funds - continued           
       GW&K SMALL-MID CAP CORE EQUITY FUND         171,932 
    *  NORTHERN TRUST COLLECTIVE ACWI ex-U.S. INDEX FUND         154,276 
    *  NORTHERN TRUST COLLECTIVE SHORT TERM INVESTMENT FUND         12,293 
       PIMCO TOTAL RETURN FUND         212,742 
       SSGA RUSSELL SMALL/MID CAP INDEX FUND CLASS K         865,253 
       SSGA S&P 500 INDEX FUND CLASS K         2,317,737 
       SSGA U.S. BOND INDEX FUND CLASS K         156,209 
       SSGA TARGET RETIREMENT 2020         196,946 
       SSGA TARGET RETIREMENT 2025         405,218 
       SSGA TARGET RETIREMENT 2030         571,713 
       SSGA TARGET RETIREMENT 2035         563,164 
       SSGA TARGET RETIREMENT 2040         476,607 
       SSGA TARGET RETIREMENT 2045         422,489 
       SSGA TARGET RETIREMENT 2050         345,438 
       SSGA TARGET RETIREMENT 2055         228,773 
       SSGA TARGET RETIREMENT 2060         130,750 
       SSGA TARGET RETIREMENT 2065         41,540 
       SSGA TARGET RETIREMENT INCOME         120,357 
       Total Collective trust funds         9,592,890 
                   
       Futures contracts           
       FUT MAR 25 IMMEMINI MDCP         (629)
       FUT MAR 25 IMMEMINI MDCP         629 
       Total Futures contracts         - 
                   
       Corporate debt           
       AMERICAN HONDA FIN CORP FLTG  02-12-2025         6,602 
       AVOLON HLDGS FDG 2.875% DUE 02-15-2025         5,881 
       BANK OF AMERICA CORPORATION MTN 3.384% DUE  04-02-2026         1,893 
       BARCLAYS PLC 3.65% DUE 03-16-2025         2,493 
       BOEING CO 2.25% DUE 06-15-2026         384 
       BOEING CO FIXED 2.196% DUE 02-04-2026         970 
       CARLYLE GLOBAL MARKET STRATEGI  14/08/2030 0% 08-14-2030         349 
       CARMAX AUTO OWNER 3.49% DUE 02-16-2027         824 
       CARMAX AUTO OWNER TRUST SER 22-4 CL A3 5.34% DUE 08-16-2027 REG         2,292 
       CHASE AUTO OWNER TR 2023-A ASSET BACKED NT CL A-2 144A 5.9% 03-25-2027         1,055 
       CHASE AUTO OWNER TR 2024-5 NT CL A-2    144A 4.4% 11-26-2027         1,298 
       CITIGROUP INC 3.106% DUE 04-08-2026         9,653 
       COLUMBIA / HCA 7.69% DUE 06-15-2025         2,023 
       CVS CAREMARK CORP DISC COML PAPER 4/2   YRS 1&2 01-31-2025         4,081 
       DEUTSCHE BK AG N Y FLTG RT 2.129% DUE  11-24-2026         1,949 
       DLLAD 2024-1 LLC 5.5% DUE 08-20-2027         2,006 
       ELEVATION CLO FLTG RT 0% DUE 07-25-2034         1,500 
       ELLINGTON FINL MTG TR 2022-1 MTG PASS THRU CTF CL A-1 2.206% 01-25-2067         2,015 
       FORD CR AUTO LEASE TR 2023-B FLTG RT SR 23-B CL A2B 02-15-2026         463 
       FORD CR AUTO LEASE TR 2024-B SR 24-B CL A2B FLTG RT 02-15-2027         2,889 
       FORD CR AUTO OWNER 5.4% DUE 04-15-2027         7,033 
       FORD CREDIT AUTO LEASE TRUST SER 23-A CL A3 4.94% 03-15-2026         920 
       FORD MTR CR CO LLC  4.134% DUE 08-04-2025         3,593 
       FORD MTR CR CO LLC 4.687%  06-09-2025         3,292 
       FORD MTR CR CO LLC 5.125% DUE 06-16-2025         1,499 
       GENERAL MTRS FINL CO INC CORP 2.9%   02-26-2025         3,986 
       GEORGIA PWR CO FLTG RT 05-08-2025         3,006 
       GOLDMAN SACHS FLTG RT 5.11322% DUE  12-09-2026         3,407 
       GS MTG BACKED SECS 5% DUE 01-25-2052         2,272 
       HARLEY DAVIDSON 3.5% DUE 07-28-2025         1,698 

     

    32

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Corporate debt - continued           
       HCA INC 5.25% DUE 04-15-2025         1,502 
       HCA INC 5.375% DUE 02-01-2025         1,670 
       HCA INC 5.875% DUE 02-15-2026         603 
       HSBC HLDGS PLC FLTG RT 2.999% DUE  03-10-2026         797 
       HSBC HLDGS PLC FLTG RT 4.292% DUE  09-12-2026         1,991 
       LLOYDS BANKING GROUP 3.511% DUE  03-18-2026/03-18-2025 BEO         299 
       MERCEDES-BENZ AUTO LEASE TRUST SR 24-B CL A2B FLTG RT 12-15-2026         4,001 
       MFA 2020-NQM2 TR 1.381% DUE 04-25-2065         292 
       MITSUBISHI UFJ FINL GROUP INC 3.837%  04-17-2026         4,041 
       MITSUBISHI UFJ FINL GROUP INC 5.541% DUE04-17-2026         801 
       MIZUHO FINL GROUP INC FLTG  05-22-2026         2,205 
       MORGAN STANLEY BANK FRN 10-15-2027         6,006 
       NAVIENT PRIVATE ED LN TR 2020-I 5.43366%04-15-2069         1,154 
       NEUBERGER BERMAN CLO LTD 20/04/2031 1.29400002956% 04-21-2031         3,829 
       NOMURA HLDGS INC 2.648%  01-16-2025         6,094 
       NXP B V / NXP FDG LLC / NXP USA INC SR  NT 2.7% 05-01-2025         298 
       OBX 2022-NQM1 TR MTG BACKED NT CL A-1   144A 2.30500006676% 11-25-2061         1,817 
       OBX 2022-NQM2 TR VAR RT 2.783% DUE      01-25-2062         606 
       ONEOK INC 4.25%  09-24-2027         1,183 
       PAC GAS & ELEC CO FIXED 3.45% DUE  07-01-2025         893 
       PAC GAS & ELEC CO FLTG RT 5.289197% DUE 09-04-2025         4,908 
       PNC BANK NA FLTG 01-15-2027         3,401 
       PVTPL ABN AMRO BANK NV 6.575%  10-13-2026         4,042 
       PVTPL ARES XXVII CLO LTD SR 13 2A CL A-R3 FLTG 10-28-2034         2,000 
       PVTPL ATLANTIC AVE 2024-3 LTD SR 24-3A CL A FLTG 01-20-2035         2,000 
       PVTPL BAIN CAPITAL CREDIT CLO LIMITED SR 20-2A CL ARR FLTG RT 07-19-2034         3,105 
       PVTPL BAIN CAPITAL CREDIT CLO LTD SR 21-3A AR FLTG RT 07-24-2034         250 
       PVTPL BANK OF AMERICA AUTO TRUST SER 23-2A CL A2 5.85% 08-17-2026         2,283 
       PVTPL BANQUE FED CRED MUTUEL FLTG RT 01-23-2027         1,411 
       PVTPL BAYER US FIN II LLC  4.25% 12-15-2025         4,966 
       PVTPL CITIZENS AUTO RECEIVABLES TRUST SER 24-2 CL A2B FLTG RT 11-16-2026         1,766 
       PVTPL CMO AREIT 2021-CRE5 LTD/AREIT AREIT 2021-C SR NT CL A VAR RT 07-17-2026         342 
       PVTPL CMO COLT 2021-4 MTG LN TR MTG PASSTHRU CTF CL A-1 10-25-2066         1,691 
       PVTPL CQS US CLO LTD SER 21-1A CL AR FLTG 01-20-2035         2,003 
       PVTPL DLLMT 2024-1 LLC NT CL A-1 144A   5.353% DUE 08-20-2025 BEO         899 
       PVTPL ELECTRICITE DE FRANCE SA 3.625% 10-13-2025         1,486 
       PVTPL ENTERPRISE FLEET FINANCING LLC SR 24-2 CL A1 5.613% 05-20-2025         661 
       PVTPL GOLUB CAP PARTNERS STATIC 2024-1  LTD/G SR 24-1A CL A-1 VAR RT 04-20-2033         2,417 
       PVTPL GPMT 2021-FL3 LTD/GPMT 2021-FL3   LLC SR SECD NT CL A FLTG 07-16-2035         750 
       PVTPL HYUNDAI AUTO LEASE SECURITIZATION TR 202 FLTG RT SR 23-C CL A2B 03-16-2026         2,024 
       PVTPL KKR CLO 9 LTD / KKR CLO 9 LLC  15/07/2030 VAR RT DUE 07-15-2030 BEO         886 
       PVTPL LCM 31 LTD SR SECD NT CL A-R FLTG 07-20-2034         1,103 
       PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE  LO SR 20-FL4 CL A VAR RT DUE 11-15-2035         626 
       PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE CO SER 21-FL7 CL A FLTG RT DUE 10-18-2036         2,929 
       PVTPL NAVIENT PRIVATE ED REFI LN TR     2021-G CL A 1.58% DUE 04-15-2070 BEO         1,275 
       PVTPL NAVIENT PRIVATE ED REFI LN TR SRS 20-HA  CL  A 1.31% DUE 01-15-2069         615 
       PVTPL NAVIENT STUDENT LN TR 2014-1 SR   22-A CL A 2.23% 07-15-2070         957 
       PVTPL NELNET STUDENT LN TR FLTG RT SER 19-2A CL A 06-27-2067 BEO         1,113 
       PVTPL NISSAN MTR ACCEP CO LLC NT  1.85%   09-16-2026         846 
       PVTPL OCTAGON INVT PARTNERS XXI  LTD/OCTAGON SR SECD NT 02-14-2031         2,283 
       PVTPL PALMER SQUARE LN FDG 2021-3 LTD/SR SECD NT CL A-1 FLTG 5.04257% 07-20-2029         407 
       PVTPL PALMER SQUARE LOAN FUNDING LTD SER 21-4A CL A1 FLTG RT 10-15-2029 BEO         561 
       PVTPL REGATTA XVI FUNDING LTD SR 19-2A CL A1R FLTG RT 01-15-2033         3,919 
       PVTPL SBA TOWER TR 4.831% 10-15-2029         1,350 
       PVTPL SOCIETE GENERALE FLTG   01-21-2026         3,001 
       PVTPL SOUND PT CLO XVI LTD/SOUND PT CLO XVI VAR RT DUE 07-25-2030 BEO         292 

     

    33

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
       Corporate debt - continued           
       PVTPL SYMPHONY CLO LTD SR 20-22A CL A1ARFLTG RT 04-18-2033         1,000 
       PVTPL TOWD POINT MORTGAGE TRUST SER 21-1 CL A1 VAR 11-25-2061         1,503 
       PVTPL TOYOTA LEASE OWNER TRUST SR 24-B CL A2B FLTG RT 02-22-2027         1,701 
       PVTPL TRILLIUM CR CARD TR II SR 23-3A CLA VAR RT DUE 08-26-2028 BEO         3,210 
       PVTPL VENTURE CLO LTD SR 17-28A CL A2R VAR RT 07-20-2030         1,825 
       PVTPL VMC FIN 2021-FL4 LLC SR SECD NT CLA 144A FLTG RATE VAR RT DUE 06-16-2036         96 
       PVTPL VOYA CLO LTD SR 19-2A CL AR FLTG 07-20-2032         1,200 
       ROGERS COMMUNICATIONS INC SR NT 2.95%   03-15-2025         2,984 
       SABINE PASS 5.625% DUE 03-01-2025         552 
       SARANAC CLO VI LTD / SARANAC CLO VI     5.69859% 08-13-2031         878 
       SOCIETE GENERALE 2.625% DUE 01-22-2025         3,995 
       SOFI PROFESSIONAL LN PROGRAM 2020-C POSTGRADUATE LN AST BKD NT 1.95% 02-15-2046         776 
       SOUTHERN CALIF EDISON CO DISC COML PAPER4/2 YRS 1&2 01-06-2025         7,994 
       T-MOBILE USA INC 3.5% 04-15-2025         2,986 
       TOYOTA LEASE OWNER FLTG RT 4.89867% DUE 04-20-2026         1,198 
       VMWARE INC FIXED 4.5% DUE 05-15-2025         6,990 
       VOLKSWAGEN AUTO FLTG RT 4.91867% DUE    01-20-2026         736 
       VOLKSWAGEN GROUP AMER FIN LLC FLTG 03-20-2026         3,299 
       WELLS FARGO & CO MEDIUM TERM SR NTS BOOKVAR RT DUE 04-25-2026/04-25-2025         2,308 
       WELLS FARGO & COMPANY 3.908%  04-25-2026         2,492 
       WORLD OMNI FLTG RT 4.77867% DUE  02-16-2027         1,693 
       Total Corporate debt         235,392 
                   
       Government debt           
       FANNIE MAE POOL #AM9004 2.8%  06-01-2025         1,741 
       FANNIE MAE SR 24-100 CL FA 5.73164%  06-25-2054         1,995 
       FANNIE MAE SR 24-103 CL FC FLTG RT 01-25-2055         997 
       FANNIE MAE SR 24-90 CL FB FLTG RT 11-25-2053         2,873 
       FANNIE MAE TR SR 24-95 CL KF FLTG  12-25-2054         1,468 
       FEDERAL HOME LN MTG CORP SER 5442 CL FB FLTG 08-25-2054         2,918 
       FHLMC SR 5480 CL FG FLTG RT 12-25-2054         981 
       FNMA FLTG RT 11-05-2027         6,001 
       FNMA REMIC TR 2024-101 CL-FB VAR  5.45201% 01-25-2055         1,993 
       FNMA REMIC TR 2024-104 CL-FA VAR 5.40201% 01-25-2055         994 
       FREDDIE MAC MULTICLASS SR 5410 CL FB    FLTG RT 05-25-2054         1,420 
       FREDDIE MAC SR 5484 CL FA FLTG RT 12-25-2054         2,049 
       GNMA 2016-H17 MTG PASS THRU CTF CL MX FC08-20-2066         325 
       GNMA 2016-H20 REMIC PASSTHRU CTF CL     MX-PT 09-20-2066         737 
       GNMA REMIC PASSTHRU SER 2016-H11 CLS F 05-20-2066         60 
       GNMA SR 23-H22 CL FB FLTG RT 09-20-2073         3,013 
       UNITED STATES TREAS NTS 4.25% 11-30-2026         102,272 
       US TREASURY N/B 3.625% 08-31-2029         14,038 
       US TREASURY N/B 4.125% 11-30-2029         8,897 
       UNITED STATES TREASURY BILLS 0% 03-27-2025         40 
       Total Government debt         154,812 
                   
       Private 40-Act mutual funds           
       PIMCO SHORT-TERM FLOATING NAV PORTFOLIO II         393,035 
       Total Private 40-Act mutual funds           

     

    34

     

     

    Abbott Laboratories Stock Retirement Plan

    EIN: 36-0698440, Plan Number: 334

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

    December 31, 2024

    (Dollars in thousands)

     

     

          (c) Description       
          of investment       
          including       
          maturity date &     (e) Current 
    (a)  (b) Identity of issue, borrower, lessor, or similar party  range of interest  (d) Cost **  value 
                   
          Interest rates 3.25% to 9.75%     
    *  Loans to participants  Maturing 2025 through 2047   100,167 
                   
                $15,676,770 

     

    *Represents a party-in-interest transaction.

    **Cost information omitted as all investments are fully participant directed.                

     

    35

     

     

    FINANCIAL STATEMENTS AND

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

    ABBOTT LABORATORIES STOCK RETIREMENT PLAN (PUERTO RICO) 

    DECEMBER 31, 2024 and 2023

     

     

     

     

    C O N T E N T S

     

      Page
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 3
       
    FINANCIAL STATEMENTS  
       
    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS 5
       
    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS 6
       
    NOTES TO FINANCIAL STATEMENTS 7
       
    SUPPLEMENTAL SCHEDULE  
       
    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) 17

     

     

     

     

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

     

    Plan Administrator and Plan Participants
    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

     

    Opinion on the financial statements

     

    We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America.

     

    Basis for opinion

     

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

     

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

     

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

     

    3

     

     

    Supplemental information

     

    The schedule of assets (held at end of year) as of December 31, 2024 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

     

    /s/ GRANT THORNTON LLP

     

    We have served as the Plan’s auditor since 2014.

     

    Chicago, Illinois
    June 20, 2025

     

    4

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS

    December 31, 2024 and 2023

    (Dollars in thousands)

     

     

       2024   2023 
    Assets          
    Cash  $27   $- 
    Investments, at fair value   237,222    217,659 
    Notes receivable from participants   5,803    5,172 
    Due from brokers   22    16 
    Accrued interest income   225    54 
               
    Total assets   243,299    222,901 
               
    Liabilities          
    Cash overdraft   -    21 
    Accrued expenses   -    1 
    Due to brokers   -    3 
               
    Total liabilities   -    25 
               
    NET ASSETS AVAILABLE FOR BENEFITS  $243,299   $222,876 

     

    The accompanying notes are an integral part of these statements.

     

    5

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

    Year ended December 31, 2024

    (Dollars in thousands)

     

     

    Additions    
    Contributions    
    Employer  $2,518 
    Participant   5,173 
          
    Total contributions   7,691 
          
    Investment income     
    Net appreciation in fair value of investments   20,681 
    Interest and dividends   5,529 
          
    Net investment income   26,210 
          
    Interest income on notes receivable from participants   355 
          
    Net additions   34,256 
          
    Deductions     
    Benefits paid to participants   13,810 
    Other expenses   23 
          
    Total deductions   13,833 
          
    NET INCREASE   20,423 
          
    Net assets available for benefits     
    Beginning of year   222,876 
          
    End of year  $243,299 

     

    The accompanying notes are an integral part of this statement.

     

    6

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    NOTES TO FINANCIAL STATEMENTS

    December 31, 2024 and 2023

     

     

    NOTE A - DESCRIPTION OF THE PLAN

     

    The following description of the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

     

    General

     

    The Plan was established January 1, 2013 in conjunction with Abbott Laboratories (“Abbott”) separating into two publicly traded companies – Abbott and AbbVie Inc. (“AbbVie”). The Plan covers employees of Abbott’s selected subsidiaries and affiliates in Puerto Rico (the “Company”).

     

    The Plan is a profit-sharing plan containing a cash or deferred arrangement intended to qualify for favorable tax treatment under sections 1081.01 (a) and (d) of the Puerto Rico Internal Revenue Code of 2011, as amended. In addition, the Plan provides an arrangement by which employees may invest in Abbott shares. Employees of the Company may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

     

    The Plan’s sponsor is Abbott Healthcare (Puerto Rico) Ltd. Alight Solutions serves as the record keeper of the Plan. The Northern Trust Company (“Custodian”) and Banco Popular de Puerto Rico (“Trustee”) serve as the Plan’s custodian and trustee, respectively. The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

     

    Contributions and Vesting

     

    Contributions to the Plan are paid to a trust administered by the Trustee. An investment committee (the “Committee”) may direct the Trustee to establish investment options of the Committee’s choosing.

     

    Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate may contribute from 2% (or 1%, for Abbott Green participants) to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from either pretax earnings or after-tax earnings, or both. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contribution are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options, except for investment options closed to new contributions.

     

    7

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE A - DESCRIPTION OF THE PLAN - Continued

     

    Contributions and Vesting - Continued

     

    Employer matching contributions to the Plan are made each payroll period based on the participating employees’ eligible earnings. Excluding the Abbott Green participants, the employer contribution for the year ended December 31, 2024 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan. Effective with the first pay period ending after March 1, 2017, employer matching contributions for Abbott Green participants are made at the rate of 100% up to a 3% deferral of eligible earnings. Employer contributions are invested each pay period according to the participant’s investment elections.

     

    In connection with the January 1, 2013 separation of Abbott into two publicly traded companies, Abbott shareholders received as a tax-free distribution one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Plan participants may continue to hold the AbbVie stock they received from the distribution; however, they may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan. AbbVie dividends are invested in the Plan’s default investment option.

     

    Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other investment options available to the participants.

     

    Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

     

    Service  Vesting percentage 
    Less than two years      0%
    Two years or more  100%

     

    A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65.

     

    Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in matching contributions upon qualifying disability.

     

    Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date. Forfeitures are used to (1) restore any forfeitures of participants who

     

    8

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE A - DESCRIPTION OF THE PLAN - Continued

     

    Contributions and Vesting - Continued

     

    returned to service with the Company within a given period of time, (2) pay Plan expenses as deemed appropriate by the administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2024, approximately $106,700 of forfeitures were used to reduce employer contributions. Forfeitures totaling approximately $109,300 and $118,200 were available at the end of 2024 and 2023, respectively.

     

    Distributions and In-Service Withdrawals

     

    Following retirement, termination or death, participants or their beneficiaries may elect to receive a distribution in installments, a single lump sum or a partial lump sum. Participants may elect a direct rollover of their accounts. Interest, dividends and other earnings will continue to accrue on any deferred amounts prior to distribution.

     

    Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, are subject to certain limitations.

     

    Notes Receivable from Participants

     

    Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to Puerto Rico Internal Revenue Code limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee’s anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee’s anticipated retirement date, if sooner). Repayment is generally made through periodic payroll deductions or by sending in a payment, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

     

    9

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     

    Basis of Accounting

     

    The financial statements have been prepared using the accrual basis of accounting.

     

    Use of Estimates

     

    The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

     

    Investment Valuation

     

    The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

     

    Common stock and mutual funds - Valued at the published market price per share or unit multiplied by the number of shares or units held.

     

    Collective trust funds and Private 40-Act mutual funds - Valued at the net asset value (“NAV”) provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

     

    The following tables summarize the basis used to measure investments at fair value at December 31, 2024 and 2023 (dollars in thousands):

     

       Basis of Fair Value Measurement     
    2024  Quoted
    Prices in
    Active
    Markets
       Significant
    Other
    Observable
    Inputs
       Significant
    Unobservable
    Inputs
       Measured at
    NAV
       Total 
    Common stock  $96,512   $-   $-   $-   $96,512 
    Mutual funds   48,681    -    -    -    48,681 
    Collective trust funds   -    -    -    92,029    92,029 
    Total investments, at fair value  $145,193   $-   $-   $92,029   $237,222 

     

    10

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

     

    Investment Valuation - Continued

     

     

       Basis of Fair Value Measurement     
    2023  Quoted
    Prices in
    Active
    Markets
       Significant
    Other
    Observable
    Inputs
      

     Significant
    Unobservable

    Inputs

       Measured at
    NAV
       Total 
    Common stock  $95,946   $-   $-   $-   $95,946 
    Mutual funds   44,900    -    -    -    44,900 
    Collective trust funds   -    -    -    76,813    76,813 
    Total investments, at fair value  $140,846   $-   $-   $76,813   $217,659 

      

    Participants are permitted to make redemptions from the Plan’s investment options on a daily basis, however, certain investments valued at NAV as a practical expedient have redemption requirements and in some cases restrictions for a Plan level redemption. The following tables provide the redemption requirements and restrictions, if any, for those investments as of December 31, 2024 and 2023. In addition, the tables provide the investment strategies for certain investments measured at NAV as a practical expedient, if that investment is a fund that does not file an annual report on Form 5500 as a direct-filing entity.

     

       2024 
       Fair value   Redemption   Redemption     
       (NAV)   frequency   notice period   Restrictions 
    Funds filing as direct filing entity:                
    Collective trusts  $92,029    Daily    0 - 5 days    -- 

     

    11

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

     

    Investment Valuation - Continued

     

       2023
       Fair value
    (NAV)
       Redemption
    frequency
      Redemption
    notice period
      Restrictions
    Funds filing as direct filing entity:              
    Collective trusts  $76,813   Daily  0 - 5 days  --
    Funds not filing as direct filing entity:              
    Private 40-Act mutual funds              
    Asset-backed securities   293   Daily  --  Yes (a)
    Corporate fixed income   556   Daily  --  Yes (a)
    Inflation-indexed bonds   80   Daily  --  Yes (a)
    International fixed income   227   Daily  --  Yes (a)
    Mortgage-related securities   301   Daily  --  Yes (a)
    Municipal fixed income   25   Daily  --  Yes (a)
    Short-term fixed income   96   Daily  --  Yes (a)
    U.S. Government securities   405   Daily  --  Yes (a)
        1,983          
       $78,796          

     

    (a)The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of $250,000 or 1% of the respective fund’s net assets during any 90-day period for any one shareholder. In consideration of the best interests of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount in whole or in part by a distribution in kind of securities held by the respective fund in lieu of cash. It is highly unlikely that shares would ever be redeemed in kind. Redemption proceeds are ordinarily wired within three business after receipt of the redemption request, but may take up to seven days.

     

    Notes Receivable from Participants

     

    Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

     

    Income Recognition

     

    Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

     

    12

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

     

    Contributions

     

    Contributions from Plan participants and the matching contributions from the employer are recorded in the year in which the employee contributions are withheld from compensation.

     

    Administrative Expenses

     

    Participants are charged transaction fees for loan processing, which are included in other expenses and commissions on purchases and sales of Abbott shares and sales of AbbVie shares, which are included in net appreciation in fair value of investments. Investment fees for mutual funds and collective trusts are charged against the net assets of the respective fund and are also included in net appreciation in fair value of investments. The Company pays other record-keeping and administration fees, where applicable. Expenses paid by the Company are excluded from these financial statements.

     

    Payment of Benefits

     

    Benefits are recorded when paid.

     

    NOTE C - INVESTMENTS

     

    Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

     

    A summary of Abbott common share data as of December 31, 2024 and 2023 is presented below:

     

       2024   2023 
    Abbott common shares, 553,452 and 581,107 shares, respectively (dollars in thousands)  $62,601   $63,962 
    Market value per share  $113.11   $110.07 

     

    NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

     

    The Plan holds units of collective trust funds managed by the Custodian. A significant portion of the Plan’s assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2024, the Plan received $1,243,000 in common stock dividends from Abbott.

     

    13

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS - Continued

     

    Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

     

    NOTE E - PLAN TERMINATION

     

    The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

     

    NOTE F - TAX STATUS

     

    The Plan received letters dated April 19, 2016 and December 2, 2019 from the Department of the Treasury of the Commonwealth of Puerto Rico that the Plan, as written, qualifies under Section 1081.01(a) of the Puerto Rico Internal Revenue Code of 2011, as amended and, consequently, its enabling trust is exempt from local income tax. The Plan has been amended since receiving the letters. The Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable Puerto Rico Internal Revenue Code.

     

    Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2024 and 2023, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress.

     

    14

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    December 31, 2024 and 2023

     

     

    NOTE G - RISKS AND UNCERTAINTIES

     

    In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

     

    NOTE H – SUBSEQUENT EVENTS

     

    Management of the Plan has evaluated subsequent events from December 31, 2024 through the date these financial statements were issued. Other than described below, management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

     

    Effective January 1, 2025, forfeitures will be used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, and (2) reduce future employer contributions if terminated participants do not return to service within the given period of time.

     

    15

     

     

    SUPPLEMENTAL SCHEDULE

     

     

     

     

    Abbott Laboratories Stock Retirement Plan (Puerto Rico)

    EIN: 98-1051267, Plan Number: 002

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)

    December 31, 2024

    (Dollars in thousands)

     

     

            (c) Description          
            of investment          
            including          
            maturity date &       (e) Current  
    (a)   (b) Identity of issue, borrower, lessor, or similar party   range of interest   (d) Cost **   value  
        Common stock - employer securities                
    *   Abbott Laboratories, common shares           $ 62,601  
                         
        Common stock                
        AbbVie Inc., common stock             33,911  
        Total Common stock             96,512  
                         
        Mutual funds                
        American Funds EuroPacific Growth Fund             5,702  
        American Funds The Growth Fund of America Fund             19,845  
        American Funds Washington Mutual Investors Fund             4,837  
        PIMCO All Asset Fund             2,582  
        PIMCO Short Asset Investment Fund             11,815  
        Vanguard Mid-Cap Value Index Fund Admiral             3,900  
        Total Mutual funds             48,681  
                         
        Collective trust funds                
        Blackrock International Opportunities Fund             1,982  
        GW&K Small-Mid Cap Core Equity Fund             3,206  
    *   Northern Trust Collective ACWI ex-U.S. Index Fund             897  
    *   Northern Trust Collective Short Term Investment Fund             178  
        PIMCO Total Return Fund             2,211  
        SSGA Russell Small/Mid Cap Index Fund             4,029  
        SSGA S&P 500 Index Fund             20,151  
        SSGA U.S. Bond Index Fund             1,661  
        SSGA Target Retirement 2020             3,902  
        SSGA Target Retirement 2025             9,974  
        SSGA Target Retirement 2030             11,602  
        SSGA Target Retirement 2035             7,492  
        SSGA Target Retirement 2040             7,205  
        SSGA Target Retirement 2045             5,740  
        SSGA Target Retirement 2050             3,456  
        SSGA Target Retirement 2055             2,097  
        SSGA Target Retirement 2060             780  
        SSGA Target Retirement 2065             474  
        SSGA Target Retirement Income             4,992  
        Total Collective trust funds             92,029  
                         
            Interest rates 3.25% to 8.50%        
    *   Loans to participants   Maturing 2025 through 2038     5,803  
                    $ 243,025  

     

    *Represents a party-in-interest transaction. 

    **Cost information omitted as all investments are fully participant directed.

     

    17

     

     

    EXHIBIT INDEX

     

    Exhibit No.  Exhibit
    23.1  Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan.
        
    23.2  Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan (Puerto Rico).

     

     

     

     

    SIGNATURE

     

    The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

     

    Date: June 20, 2025 By: /s/ Sean J. Treacy
          Sean J. Treacy
          Plan Administrator

     

     

     

    Get the next $ABT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    5/30/2023$112.00Overweight → Equal-Weight
    Morgan Stanley
    4/20/2023$125.00 → $127.00Overweight
    Barclays
    More analyst ratings

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Abbott's Latest-Generation FreeStyle Libre 3 Plus Glucose Sensor Technology Launches in Canada

      Abbott continues to transform diabetes care with its leading Libre systems and the new FreeStyle Libre 3 Plus* sensor MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE:ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus* sensor, is now available to Canadians living with diabetes. This innovative product features the world's smallest1,2 glucose sensor. Glucose monitoring is key to effective diabetes management as it helps people living with diabetes understand how their body responds to food, exercise, and

      7/8/25 8:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Hosts Conference Call for Second-Quarter Earnings

      ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

      6/26/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier

      Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status.Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes.CHICAGO, June 20, 2025 /PRNewswire/ -- Late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Abbott's (NYSE:ABT) Healthy Food Rx "food is medicine" program helped people living with diabetes

      6/20/25 7:30:00 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

      10/24/23 3:52:17 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Abbott Labs with a new price target

      Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

      6/16/25 8:17:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Abbott Labs with a new price target

      Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00

      10/8/24 7:11:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Abbott Labs with a new price target

      Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00

      9/19/24 7:31:59 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/13/24 4:55:58 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/9/23 10:54:50 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/9/22 3:15:56 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Stratton John G

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      7/1/25 5:32:18 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Roman Michael F

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      7/1/25 5:24:18 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gonzalez Patricia Paola

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      7/1/25 5:13:51 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    SEC Filings

    See more
    • SEC Form 11-K filed by Abbott Laboratories

      11-K - ABBOTT LABORATORIES (0000001800) (Filer)

      6/20/25 4:05:52 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Abbott Laboratories

      SD - ABBOTT LABORATORIES (0000001800) (Filer)

      5/29/25 11:01:45 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Laboratories filed SEC Form 8-K: Leadership Update

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      5/1/25 4:01:21 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Financials

    Live finance-specific insights

    See more
    • Abbott Hosts Conference Call for Second-Quarter Earnings

      ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

      6/26/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Declares 406th Consecutive Quarterly Dividend

      ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 406th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio

      6/13/25 11:34:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

      First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increaseReported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increaseABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025. First-quarter sales increased 4.0 percent on a reported basis, 6.9 pe

      4/16/25 7:30:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    See more
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate